

**International Consortium for Harmonization of Clinical Laboratory Results**  
**Harmonization Oversight Group / Council Conference Call Meeting**

**DATE:** 28 February 2017

**TIME:** 7:00 a.m. to 8:00 a.m. EST

**HOG Members:**

Dr. Greg Miller (Chair)  
Dr. Eunice Lee (Vice-Chair)  
Mr. Joseph Passarelli  
Dr. Tony Killeen  
Dr. Steve Master

**ICHCLR Council Members:**

Dr. Gary Myers (chair)  
Mr. Hirofumi Koide  
Dr. Katsuyuki Nakajima  
Dr. Hideo Kato

**HOG Members Absent:**

Dr. Naotaka Hamasaki  
Dr. Amy Saenger  
Dr. Ian Young

**Council Members Absent:**

Dr. Junghan Song

**AACC Staff:**

Ms. Stefanie Kleinman (Scientific and Practice Affairs Specialist)

**Minutes:**

1. The test new web site was reviewed. The new site is undergoing conversion from AACC to Insoft and is expected to be live any day. A sentence will be added to the measurand table informing readers they can comment on prioritizations or other content using the contact us tab.
2. The IFCC task force report regarding reorganizing the ICHCLR was reviewed. Feedback from the IFCC Executive Board is anticipated in the next weeks. We will respond according to the feedback received.
3. The Strategic Partners Update draft was reviewed. It will be circulated as soon as the new web site is activated.
4. Several reports on measurand harmonization were reviewed and prioritizations agreed. The new information will be posted to the new web site when the justifications are written (see assignments below). Additional measurands on the prioritization spreadsheet were reviewed. The following actions were taken.

Measurand	Decision	Assigned to
Anti-HCV Ab	Low priority	Steve will write justification; address the need for standardization near the decision value for positive
HIV-1 Ag with HIV-1 and HIV-2 Abs	Adequate harmonization	
HIV-RNA	Medium priority	Tony will write justification
HBV Ag and anti-HBs Ab	Adequate harmonization	
Folate	Medium priority	Gary will contact Christine Pfeiffer and write justification
Protein S		Steve to ask a colleague regarding clinical importance. Greg to email Hamasaki regarding clinical impact.
CO2		Greg has crossover data with 4 mmol/L constant bias. Steve to review crossover data.
D-Dimer		Steve to review PT data
Tacrolimus		Ian to review
HCV RNA	?	?
HCG		Steve to contact Ann Gronowski.
CMV DNA quant		Greg contact Angie Caliendo

Vancomycin		Amy to review or recommend
Ethyl alcohol		Greg to review literature
Various drugs		Greg to contact Tom Annesley, Fred Apple, Paul Janetto, Bill Clarke for advice
methemoglobin		Eunice to investigate
EBV DNA quant	Uncertain	Gary and Tony to follow up
T.pallidum		Greg ask micro at VCU
unsat iron binding capacity	Adequate harmonization	
fibrin/fibrinogen degradation products		Tony to ask Chuck Eby at Wash U
rheumatoid factor		Tony to review literature
T3 free		Greg check CAP survey
PSA		Steve add to current justification at low values as trigger for treatment

5. Next call at 7-8 AM USA Eastern time

April 5 (daylight saving time; GMT-4)